ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

Johnson & Johnson (JNJ) reported robust second-quarter 2025 results, surpassing consensus estimates with $2.77 EPS and $23.74 billion in revenue, driven by strong performances in Innovative Medicines and MedTech despite a significant decline in Stelara sales due to biosimilar competition. The company subsequently raised its full-year 2025 revenue guidance to $93.2-$93.6 billion and adjusted EPS to $10.80-$10.90, citing a stronger top-line outlook and reduced tariff impact. JNJ shares rallied 6.1% on the news, further bolstered by a 63rd consecutive annual dividend increase to $1.30 per share, signaling continued financial strength and management confidence.

Analysis

Johnson & Johnson delivered a robust second quarter for 2025, exceeding consensus estimates on both revenue and earnings. The company reported revenues of $23.74 billion, a 5.8% year-over-year increase, driven by solid growth in its MedTech segment (+7.3%) and Innovative Medicines division (+4.9%). Despite a minor 1.8% decline in year-over-year EPS to $2.77, the figure still surpassed analyst expectations. Notably, the company is successfully navigating a significant patent cliff, with strong performance from key growth products like the cancer treatment Darzalex, whose sales surged 23% to $3.5 billion, helping to offset the steep 42.7% decline in Stelara sales following the introduction of biosimilar competition. The most significant signal for investors is the substantial upward revision of full-year 2025 guidance. Management raised its revenue forecast to $93.2-$93.6 billion, implying a growth rate of 5.1%-5.6%, nearly double the prior forecast. This heightened confidence, attributed to new product launches and a lower-than-expected tariff impact, was validated by a Stifel price target increase to $165.00 and a 6.1% rally in the stock price. The company's 63rd consecutive annual dividend increase further underscores its financial stability and commitment to shareholder returns.

Key Decisions for Investors

• Given the strong earnings beat, significant guidance upgrade, and consistent dividend growth, investors may view Johnson & Johnson as a core holding with renewed momentum, justifying a hold or accumulation strategy.
• It is critical to monitor the performance of growth drivers like Darzalex and the pipeline of new products to ensure they continue to effectively offset the anticipated revenue erosion from legacy drugs like Stelara.
• For those seeking diversified exposure, broad healthcare ETFs like Health Care Select Sector SPDR Fund (XLV) offer a compelling, low-cost method to participate in JNJ's upside while mitigating single-stock risk.
• Investors should note the stock's 6.1% post-earnings rally and weigh the new $165 Stifel price target to evaluate the remaining near-term upside potential.